Comparative Pharmacology
Head-to-head clinical analysis: CEFOTETAN versus PANIXINE DISPERDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTETAN versus PANIXINE DISPERDOSE.
CEFOTETAN vs PANIXINE DISPERDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
Panixine is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1 to 2 g intravenously or intramuscularly every 12 hours. For severe infections, up to 2 g every 12 hours for 5-10 days.
Cefpodoxime proxetil (Panixine Disperdose) is administered orally (PO) as a dispersible tablet. Typical adult dose: 200 mg PO every 12 hours for 10-14 days for community-acquired pneumonia; 100 mg PO every 12 hours for 5-7 days for acute exacerbation of chronic bronchitis; 200 mg PO single dose for uncomplicated gonorrhea.
None Documented
None Documented
Clinical Note
moderateCefotetan + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefotetan."
Clinical Note
moderateCefotetan + Ethanol
"The risk or severity of adverse effects can be increased when Cefotetan is combined with Ethanol."
Clinical Note
moderateCefotetan + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefotetan."
Clinical Note
moderateCefotetan + Carbocisteine
3-4.5 hours (6-8 hours in renal impairment).
6-8 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in severe impairment).
Renal (80-90% unchanged), biliary (small amount, up to 20% in bile), fecal (<5%).
Renal excretion of unchanged drug accounts for 70-80% of elimination; biliary/fecal excretion accounts for 10-15%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The risk or severity of adverse effects can be increased when Cefotetan is combined with Carbocisteine."